RECEIVED ON

2 7 MAY 2005

## THE UNITED REPUBLIC OF TANZANIA GAVI Secrétariat MINISTRY OF HEALTH

Telegrams "AFYA"
Tel: 255-51-2120261 General
(All letters should be addressed to
The Permanent Secretary)

In reply please quote:

Ref. No. GA/222/425/01



P.O. Box 9083, DAR ES SALAAM.

May 21, 2005

Dr. Julian Lob-Levyt
Executive Secretary
Global Alliance for Vaccine Immunization (GAVI)
UNICEF, Palais des Nations
1211 Geneva 10
SWITZERLAND

#### Re: GAVI ANNUAL PROGRESS REPORT 2004

Please refer to the above subject matter.

With this letter find a copy of the duly signed GAVI Annual Progress Report for 2004.

We kindly appreciate and thank you for the invaluable support to our Immunization Programme. It is my hope that we will continue to enjoy your support in this endeavour.

I thank you.

Dr Hussein A. Mwinyi (MP)

DEPUTY MINISTER FOR HEALTH

k.n.y. KATIBU MKUU. WIZARA YA AFYA S.L.P. 9083 DAR ES SALAAM



## THE UNITED REPUBLIC OF TANZANIA MINISTRY OF HEALTH

Telegrams: "AFYA", DAR ES SALAAM Telephone: 120261 (All letters should be addressed to the Permanent Secretary) In reply please quote:



P.O. Box 9083, DAR ES SALAAM

Ref. No.GA/222/425/01

21<sup>st</sup> May, 2005

Dr. Julian Lob-Levyt
Executive Secretary
GAVI
UNICEF, Palais des Nations
1211 Geneva 10
SWITZERLAND

RE: INJECTION SAFETY SUPPORT TO TANZANIA

Please refer to the above subject matter.

On behalf of the Ministry of Health and the people of Tanzania, I would like to take this opportunity to thank Global Alliance for Vaccine and Immunization for supporting the implementation of injection safety practices in Immunization services in our country.

I am pleased to inform you that consequent to your initial support Tanzania has started purchasing auto disabled syringes for immunization services and will continue to practise injection safety practices.

Thanks for your continued support and collaboration.

Dr. Hussein A. Mwinyi (MP

DEPUTY MINISTER FOR HEALTH

Copy to:

Dr. Edward Maganu

WHO Representative for Tanzania

DAR ES SALAM

Mr. Rodney Phillips

UNICEF Representative for Tanzania

DAR ES SALAAM

January 2005



# **Progress Report**

Partnering with The Vaccine Fund

to the
Global Alliance for Vaccines and Immunization (GAVI)
and
The Vaccine Fund

by the Government of

COUNTRY:

UNITED REPUBLIC OF TANZANIA

Date of submission: 2<sup>ND</sup> APRIL, 2005.....

Reporting period: 2004 (Information provided in this report MUST refer to

2004 activities)

# ( Tick only one ): Inception report First annual progress report Second annual progress report Third annual progress report Fourth annual progress report ρ Fifth annual progress report ρ

Text boxes supplied in this report are meant only to be used as guides. Please feel free to add text beyond the space provided.

\*Unless otherwise specified, documents may be shared with GAVI partners and collaborators

#### **Progress Report Form: Table of Contents**

#### 1. Report on progress made during 2004

- 1.1 Immunization Services Support (ISS)
- 1.1.1 Management of ISS Funds
- 1.1.2 Use of Immunization Services Support
- 1.1.3 Immunization Data Quality Audit
- 1.2 GAVI/Vaccine Fund New and Under-used Vaccines
- 1.2.1 Receipt of new and under-used vaccines
- 1.2.2 Major activities
- 1.2.3 Use if GAVI/The Vaccine Fund financial support (US\$100,000) for introduction of the new vaccine
- 1.3 Injection Safety

- 1.3.1 Receipt of injection safety support
- 1.3.2 Progress of transition plan for safe injections and safe management of sharps waste
- 1.3.3 Statement on use of GAVI/The Vaccine Fund injection safety support (if received in the form of a cash contribution)

#### 2. Financial Sustainability

- 3. Request for new and under-used vaccine for 2006
  - 3.1 Up-dated immunization targets
  - 3.2 Confirmed/revised request for new vaccine (to be shared with UNICEF Supply Division) for year...
  - 3.3 Confirmed/revised request for injection safety support for the year...
- 4. Please report on progress since submission of the last Progress Report based on the indicators selected by your country in the proposal for GAVI/VF support
- 5. Checklist
- 6. Comments
- 7. Signatures
- 1. Report on progress made during 2004

To be filled in by the country for each type of support received from GAVI/The Vaccine Fund.

- 1.1 Immunization Services Support (ISS)
- 1.1.1 Management of ISS Funds

Please describe the mechanism for management of ISS funds, including the role of the Inter-Agency Co-ordinating Committee (ICC).

Please report on any problems that have been encountered involving the use of those funds, such as delay in availability for programme use.

Though the ISS funds were received in the country in March 2004, there was a delay in conducting the joint Tanzania Mainland/Zanzibar meeting to agree on how to share ISS funds between two ministries since the United Republic of Tanzania consists of two Ministries of health., A consensus meeting on how to share the ISS funds had to be conducted and disbursement of funds has started.

Low performing districts were encouraged to identify problems on how they will improve and raise immunization coverage in their districts. Problems identified include: Difficult to reach areas; areas with high dropout rates; areas with high number of unreached children; poor data management; unreliable transport in some districts; inadequate supervision. Lack of spare parts/service of cold chain equipments. Lack of reliable transport in 12 municipal councils. Lack of supportive supervision by regional EPI focal person and absence of stand by generator at central level were also among the problems identified. Based on the above problems plans were prepared and then presented to the ICC for comments. The plans were then sent to WHO for disbursement of funds.

#### 1.1.2 Use of Immunization Services Support

In 2004, the following major areas of activities have been funded with the GAVI/Vaccine Fund Immunization Services Support contribution.

Funds received during 2004 1,689,000US\$
Remaining funds (carry over) from 2003 35,294.52US\$

Table 1: Use of funds during 2004

|                              |                 | AMOUNT OF FUNDS |                       |              |                |  |  |  |  |  |
|------------------------------|-----------------|-----------------|-----------------------|--------------|----------------|--|--|--|--|--|
| Area of Immunization         | Total amount in |                 | PUBLIC SECTOR         |              | PRIVATE        |  |  |  |  |  |
| Services Support             | US \$           | Central         | Region/State/Province | District     | SECTOR & Other |  |  |  |  |  |
| Vaccines                     | 5,127,664.77    |                 |                       | 5,127,664.77 |                |  |  |  |  |  |
| Injection supplies           | 182,019.36      |                 |                       | 182,019.36   |                |  |  |  |  |  |
| Personnel                    | 398.23          | 398.23          |                       |              |                |  |  |  |  |  |
| Transportation               | 427,06          |                 |                       | 427.06       |                |  |  |  |  |  |
| Maintenance and overheads    | 3651.54         | 2815.65         | 536.26                | 299.63       |                |  |  |  |  |  |
| Training                     | 49,653          |                 |                       | 49,653       |                |  |  |  |  |  |
| IEC / social mobilization    | 17.7            | 17.7            | -                     |              |                |  |  |  |  |  |
| Outreach                     |                 |                 |                       |              |                |  |  |  |  |  |
| Supervision                  |                 |                 |                       |              |                |  |  |  |  |  |
| Monitoring and evaluation    | 14,237.97       |                 | 14237.97              |              |                |  |  |  |  |  |
| Epidemiological surveillance |                 |                 |                       |              |                |  |  |  |  |  |
| Vehicles                     |                 |                 |                       |              |                |  |  |  |  |  |
| Cold chain equipment         | 5,527.15        |                 |                       | 5527.15      |                |  |  |  |  |  |
| Other (specify)              |                 |                 |                       |              |                |  |  |  |  |  |
| Total:                       | 5,371,611       |                 |                       |              |                |  |  |  |  |  |
| Remaining funds for next     | 1,641,368.52    |                 |                       |              |                |  |  |  |  |  |
| year:                        | 2,012,20002     |                 |                       |              |                |  |  |  |  |  |

<sup>\*</sup>If no information is available because of block grants, please indicate under 'other'.

#### Please attach the minutes of the ICC meeting(s) when the allocation of funds was discussed.

Please report on major activities conducted to strengthen immunization, as well as, problems encountered in relation to your multi-year plan.

| 1.1.3 Immunization Data Quality Audit (DQA) (If it has been implemented in your country)   |
|--|
| Has a plan of action to improve the reporting system based on the recommendations from the DQA been prepared?  If yes, please attach the plan.   |
| YES NO NO  |
| If yes, please report on the degree of its implementation.   |
| There was no DQA conducted during reporting period. However, Under the current integrated approach most of the recommended activities had been in cooperated in the Council Comprehensive Health Plans. Most of the recommendations have been implemented at Health facility and District level. At National level sensitisation was conducted in all 131 districts including Zanzibar, in which best practices were shared. Sensitisation on the use and timely submission of monthly reporting forms was done. Data management training under the existing Health Management has been conducted for district and Regional Health Management Teams. Monitoring of timeliness and completeness of reporting has been introduced in collaboration with the IDSR. During annual EPI meeting more emphasis was done on proper data management and reporting. Data Quality Self assessment training was conducted for ToTs and the plan is to train regional and district level.  The data management activities have been incorporated into EPI 5 years strategic plan. DQSA training is also included. |
|  |
|  |

| Please report on studies conduc | ted regarding EPI issues during 2004 | (for example, coverage si | irveys). |  |
|---------------------------------|--------------------------------------|---------------------------|----------|--|
|                                 |                                      |                           |          |  |
|                                 |                                      |                           |          |  |
|                                 |                                      |                           |          |  |
|                                 |                                      |                           |          |  |

1.2.1 Receipt of new and under-used vaccines during 2004

Start of vaccinations with the new and under-used vaccine: JANUARY YEAR 2002

Please report on receipt of vaccines provided by GAVI/VF, including problems encountered.

100 percent of DPT-HB vaccine supported by GAVI was available in the country timely. We did not experience any problems in delivery the vaccine. Schedule: 25/2/2004- 229500doses of DPT-HB, 21/4/2004-635000 doses of DPT-HB, 2/7/2004 -642500doses of DPT-HB, 2/7/2004-591500 doses of DPT-HB, 1/9/2004-703,500 doses of DPT-HB, 6/10/2004 -1346,500 doses of DPT-HB.

#### 1.2.2 Major activities

Please outline major activities that have been or will be undertaken, in relation to, introduction, phasing-in, service strengthening, etc. and report on problems encountered.

The major activities undertaken includes Support of Annual EPI evaluation meeting, support sensitisation meeting to districts focal persons on strengthening immunization services, re-training on reducing wastage rates, injection safety practices. The other planned activities, which will be undertaken, include support of hard to reach areas.

Support regional level supportive supervision.

Due to delay in conducting meeting on how to share the funds between two Ministries, the implementation of the identified activities also delayed.

## 1.2.3 Use of GAVI/The Vaccine Fund financial support (US\$100,000) for the introduction of the new vaccine

Please report on the proportion of 100,000 US\$ used, activities undertaken, and problems encountered such as delay in availability of funds for programme use.

Though Tanzania was eligible for receiving the 100,000 US D support for vaccine introduction, we haven't received the fund despite of several reminder.

#### 1.3 Injection Safety

#### 1.3.1 Receipt of injection safety support

Please report on receipt of injection safety support provided by GAVI/VF, including problems encountered

Tanzania Mainland has received injection safety funds, and the plan is to train Health workers on proper construction of incinerator and injection safety practices. The fund will also support construction of incinerators in the remaining districts. However Zanzibar received injection safety materials and didn't encounter any problem. The GAVI supplied ADs (Medeco inject ADs type supplied from Abu Dhabi) made the health workers to encounter difficulties since there was no prior information to train health workers before the arrivals of the syringes. Clarification was

made by EPI central office and different opportunities (meetings, training and during supportive supervision) was used to train health workers on the new type of ADs syringes.

#### 1.3.2 Progress of transition plan for safe injections and safe management of sharps waste.

Please report problems encountered during the implementation of the transitional plan for safe injection and sharp waste

All ADs for other antigens are procured by the government and advocacy is for the Government to take over after the GAVI support for ADs for DPT-HepB vaccine. Districts are encouraged to construct low cost incinerators and at health facilities level all sharps should be burnt and buried.

Please report on the progress based on the indicators chosen by your country in the proposal for GAVI/VF support.

| Indicators  | Targets  | Achievements | Constraints                              | Updated targets |
|---|--|--------------|--|-----------------|
| Adequacy of supplies                                    | 100% AD syringes & safety boxes in all immunization services | 100%         | Not aware of mechanism of new ADs        | 100%            |
| Adoption of safe injection practices by Health Workers. | 90% of service providers adopt injection safety practices.   | 75%          | Inadequate training to<br>Health Workers | 80%             |
|   |  |              | Lack of appropriate training materials   |                 |
| Injections Waste disposal                               | Train 100% health workers on injection waste disposal        | 70%          | Few incinerators were constructed.       | 80%             |
| Adverse Event Following                                 | Non existence of cases of                                    | 80%          | Weak AEFI reporting system               |                 |

| Immunization | AEFI due to poor injection safety practices | Inadequate training to Health Workers | 80% |
|--------------|---|---------------------------------------|-----|
|              |   |                                       |     |

#### 1.3.3 Statement on use of GAVI/The Vaccine Fund injection safety support (if received in the form of a cash contribution)

The following major areas of activities have been funded (specify the amount) with the GAVI/The Vaccine Fund injection safety support in the past year:

Tanzania Mainland received injection safety support fund (489,000 US\$), however implementation of the identified activities not yet started. This is because the fund was received together with the ISS fund and the plan was to conduct the meeting between two Ministries and agreed on how to divide the funds between two ministries before starting using funds. Due to other commitments it took time for the two ministries to conduct the meeting, however the preparation for implementing planned activities had already started and the activities will be implemented soon.

#### 2. Financial sustainability

Inception Report:

Outline timetable and process for the development of a financial sustainability plan. Describe assistance that may be

needed for developing a financial sustainability plan.

First Annual Progress Report:

Submit completed financial sustainability plan by given deadline. Describe major strategies for improving financial

sustainability.

Tanzania participated in the orientation workshop in Nairobi in which participants from MOH (EPI and planning), MOF, WHO and UNICEF attended.

A National workshop was held in July 2002 to put up a Financial Sustainability Plan.

In August 2002, an economist was hired by WHO as a local consultant to further work on this document for both Mainland and Zanzibar.

External Consultants joined the local consultant in November 2002 to complete the Document for presentation to GAVI

Reviewers indicated some areas for improvement

The Financial Sustainability Plan, sub-working group incorporated the comments and finalized the second revised financial Sustainability Plan.

Financial Sustainability plan strategies were also developed Another external consultant came to fine tune the second draft in September 2003 A second submission was made in December 2003. Comments from second revision received are being incorporated. Revision of FSP strategies and revision of costing has started.

Subsequent Progress Reports:

According to current GAVI rules, support for new and under-used vaccines is covering the total quantity required to meet country targets (assumed to be equal to DTP3 targets) over a five year period (100% x 5 years = 500%). If the requested amount of new vaccines does not target the full country in a given year (for example, a phasing in of 25%), the country is allowed to request the remaining (in that same example: 75%) in a later year. In an attempt to help countries find sources of funding in order to attain financial sustainability by slowly phasing out GAVI/VF support, they are encouraged to begin contributing a portion of the vaccine quantity required. Therefore, GAVI/VF support can be spread out over a maximum of ten years after the initial approval, but will not exceed the 500% limit (see figure 4 in the GAVI Handbook for further clarification). In table 2.1, specify the annual proportion of five year GAVI/VF support for new vaccines that is planned to be spread-out over a maximum of ten years and co-funded with other sources. Please add the three rows (Proportion funded by GAVI/VF (%), Proportion funded by the Government and other sources (%), Total funding for ........................ (new vaccine)) for each new vaccine.

Table 2.1: Sources (planned) of financing of new vaccine .....DPT-HepB (specify)

| Proportion of vaccines supported by *                        | Annual proportion of vaccines |          |        |        |        |       |       |       |       |       |  |
|--|-------------------------------|----------|--------|--------|--------|-------|-------|-------|-------|-------|--|
| Troportion of vaccines supported by                          | 2003                          | 2004     | 2005   | 2006   | 2007   | 20    | 20    | 20    | 20    | 20    |  |
| A: Proportion funded by GAVI/VF (%)***                       | 97%                           | 80%      | 59%    | 59%    | 0%     | 0%    | 0%    | 0%    | 0%    | 0%    |  |
| B: Proportion funded by the Government and other sources (%) | 3%                            | 20%      | 41%    | 41%    | 15%    | 15%   | 15%   | 15%   | 15%   | 20%   |  |
| C: Total funding for DPT Hep B (new vaccine)                 | 4.97Mil                       | 6.2 Mil. | 6.5Mil | 7.0Mil | 7.5Mil | 8.0M1 | 8.0Ml | 8.0Ml | 8.0Ml | 8.0Ml |  |

In table 2.2 below, describe progress made against major financial sustainability strategies and corresponding indicators.

**Table 2.2:** Progress against major financial sustainability strategies and corresponding indicators

| Financial Sustainability<br>Strategy              | Specific Actions Taken<br>Towards Achieving<br>Strategy                      | Progress<br>Achieved                                       | Problems<br>Encountered   | Baseline Value of<br>Progress Indicator      | Current Value of<br>Progress Indicator | Proposed Changes To<br>Financial Sustainability<br>Strategy                                       |
|---|--|--|---|--|--|---|
| Mobilize additional local Govt resources          | Sensitisation meeting to<br>CHMTs and Health<br>Coordinators of PORALG       | EPI activities<br>are priority at<br>the district<br>level | Reliabity of the allocated resources  | Data not compiled from districts             | Data not compiled from districts       | To be able to capture district level expenditures on EPI  |
| Expansion of ICC                                  | Other partners encouraged to join ICC.                                       | One member<br>joined ICC                                   | Poor attendance<br>of ICC members   | Not Applicable                               | Not Applicable                         |   |
| Reduce vaccine wastage                            | Refresher training on<br>reducing wastage rate was<br>done to Health workers | Wastage rate reduced                                       | Weak monitoring system  | 15%  | 15%                                    | Daily sessions to be encouraged   |
| Increase vaccination offered through static units | 10 remote HFs will be supported to deliver imm. Service                      | Things to be supported identified                          | Many HFs are<br>constructed &<br>demand support   | 0  | 10 HFs will be supported               | No change proposed to this strategy   |
| Preparation of advocacy documents                 | Develop the brief / flyer<br>highlighting key FSP<br>messages                | EPI FSP<br>courted in<br>different<br>forums               | Competing priorities & good EPI performance made local partners and some decision leaders to focus other program. | Non existing brief/flyer<br>highlighting FSP | Existence of a flyer                   | Conduct advocacy meetings   |
| Mobilize additional Govt resources                | Advocacy done to decision makers   | Govt<br>resources<br>increased                             | Competing priorities  | 3.9ml US\$ (2003/04)                         | 5.4 ml. US\$ (2004/05)                 | Establish evidence ( impact, opportunistic cost etc ) and present to decision makers and partners |
|   | Meetings with top Ministry of<br>Health officials regarding                  | Meeting done   | Lack of local evidence  | One meeting conducted                        | Three meeting conducted                | No change proposed to this strategy   |

<sup>\*</sup> Percentage of DTP3 coverage (or measles coverage in case of Yellow Fever) that is target for vaccination with a new and under-used vaccine.

<sup>\*\*</sup> The first year should be the year of GAVI/VF new vaccine introduction \*\*\* Row A should total 500% at the end of GAVI/VF support

|  | Govt, Policy and Planning   |   |   |  |   |                                     |
|--|---|---|---|--|---|-------------------------------------|
|  | Meeting with key Government ministries Presidents office, planning and privatization, state house, prime ministers office     |   |   |  |   | No change proposed to this strategy |
|  | Presentation of FSP information memorandum to cabinet   | Not done  |   | NA   | NA                                      | No change proposed to this strategy |
| Increase reliability of public resources             | Identify and highlight funding<br>gap in the present planning<br>cycle for the Govt (Medium<br>Term Expenditure<br>Framework) | EPI gap<br>identified &<br>presented in<br>Health sector<br>review<br>meetings                            |   | Not sure of exact the EPI gap  | Exact EPI gap is known                  | No change proposed to this strategy |
|  | Ensure program funding needs are included in the MTEF   | Program<br>needs are<br>included in<br>the MTEF   | Competing priorities allocation is not 100%             | Not all activities were included in the MTEF                         | All activities are included in the MTEF | No change proposed to this strategy |
|  | Advocate for protection/ring<br>fencing of the bulk of<br>program funds from Govt<br>(particularly for vaccine<br>purchases)  | EPI funds are protected no reallocation all vaccines in exception of DPT-Hep B are procured by government | Several request<br>for reallocation by<br>other program | Reallocation of funds for<br>other activities apart from<br>vaccines | Rear reallocation                       | No change proposed to this strategy |
|  |   |   |   |  |   |                                     |
| Use of performance standards by centre for districts | Agreement on indicators to measure districts performance against each other   | Indicators identified   | Identifying one<br>district from 119<br>districts       | No reward given  | Reward prepared for best district       | No change proposed to this strategy |
|  | Information on performance<br>of districts reported in regular<br>ICC meetings  | District<br>performance<br>is shared to all   | Poor monthly reporting                                  | Once per year  | 4 times a year                          | No change proposed to this strategy |

#### 3. Request for new and under-used vaccines for year 2006

Section 3 is related to the request for new and under used vaccines and injection safety for 2006.

#### 3.1. <u>Up-dated immunization targets</u>

Confirm/update basic data approved with country application: figures are expected to be consistent with those reported in the WHO/UNICEF Joint Reporting Forms. Any changes and/or discrepancies MUST be justified in the space provided (page 12). Targets for future years MUST be provided.

Table 3: Update of immunization achievements and annual targets

| Number of   |           | Achievements and targets |           |           |           |           |           |           |           |  |  |  |
|---|-----------|--------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|--|--|--|
| Number of   | 2004      | 2005                     | 2006      | 2007      | 2008      | 2009      | 2010      | 2011      | 2012      |  |  |  |
| DENOMINATORS  | 1,356,054 | 1,398,960                | 1,439,530 | 1,481,276 | 1,524,232 | 1,568,435 | 1,613,920 | 1,660,724 | 1,708,884 |  |  |  |
| Births  | 1,498,830 | 1,545,876                | 1,590,707 | 1,636,837 | 1,684,305 | 1,733,149 | 1,783,411 | 1,835,130 | 1,888,349 |  |  |  |
| Infants' deaths   | 177,179   | 185,897                  | 191,288   | 196,835   | 202,543   | 208,417   | 214,461   | 220,681   | 227,080   |  |  |  |
| Surviving infants   | 1,356,054 | 1,398,960                | 1,439,530 | 1,481,276 | 1,524,232 | 1,568,435 | 1,613,920 | 1,660,724 | 1,708,884 |  |  |  |
| Infants vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with 1 <sup>st</sup> dose of DTP (DTP1)*  Infants vaccinated 2004 (JRF) / to be vaccinated in 2005 and beyond with 3 <sup>rd</sup> dose of DTP (DTP3)* |           |                          |           |           |           |           |           |           |           |  |  |  |
| NEW VACCINES **  Infants vaccinated 2004 (JRF) / to be vaccinated in 2005 and beyond with 1 <sup>st</sup> dose of DTP (DTP1)*   | 1,355,922 | 1,398,960                | 1,439,530 | 1,481,276 | 1,524,232 | 1,568,435 | 1,613,920 | 1,660,724 | 1.708.884 |  |  |  |

| Infants vaccinated 2004 (JRF) / to be vaccinated in 2005 and beyond with 3 <sup>rd</sup> dose of (new vaccine)  Wastage rate in 2004 and plan for 2005 beyond*** (new vaccine) | _ <u>1,282,278</u><br>_ 15% | _1,326,402<br>_15% | _1,379,226<br>_10% | _1,433,998<br>_10% | 1,490 <u>,</u> 357<br>10% | _ <u>1,548,778</u><br>_ 10% | _ <u>1,593,692</u><br>10% | _ 1,639,909 _<br>10% | _1,639,630 <u>]</u> |
|--|-----------------------------|--------------------|--------------------|--------------------|---------------------------|-----------------------------|---------------------------|----------------------|---------------------|
| INJECTION SAFETY****   |                             |                    |                    |                    |                           |                             |                           |                      |                     |
| Target for pregnant women to be vaccinated   | 1,498,830                   | 1,545,876          | 1,590,707          | 1,636,837          | 1,684,305                 | 1,733,149                   | 1,783,411                 | 1,835,130            | 1,888,349           |
| Pregnant women vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with TT2   | 1,192,270                   | 1,369,359          | 1,425,421          | 1,483,584          | 1,543,921                 | 1,606,026                   | 1,670,435                 | 1,737,229            | 1,805,965           |
| Infants vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with BCG *  | 1,369,596                   | 1,545,876          | 1,590,707          | 1,636,837          | 1,684,305                 | 1,733,149                   | 1,783,411                 | 1,835,130            | 1,888,349           |
| Infants vaccinated in 2004 (JRF) / to be vaccinated in 2005 and beyond with Measles *  | 1,275,352                   | 1,326,797          | 1,379,633          | 1,433,998          | 1,490,357                 | 1,548,778                   | 1,593,692                 | 1,639,909            | 1,687,467           |

<sup>\*</sup> Indicate actual number of children vaccinated in 2004 and updated targets (with either DTP alone or combined)

Please provide justification on changes to baseline, targets, wastage rate, vaccine presentation, etc. from the previously approved plan, and on reported figures which differ from those reported in the WHO/UNICEF Joint Reporting Form in the space provided below.

2002 census

The new growth rate for each district was used to calculate the coverage.

<sup>\*\*</sup> Use 3 rows (as indicated under the heading NEW VACCINES) for every new vaccine introduced

<sup>\*\*\*</sup> Indicate actual wastage rate obtained in past years

<sup>\*\*\*\*</sup> Insert any row as necessary

### 3.2 Availability of revised request for new vaccine (to be shared with UNICEF Supply Division) for 2006

In case you are changing the presentation of the vaccine, or increasing your request; please indicate below if UNICEF Supply Division has assured the availability of the new quantity/presentation of supply.

NA .

Table 4: Estimated number of doses of ...... vaccine (specify for one presentation only): Please repeat this table for any other vaccine presentation requested from GAVI/The Vaccine Fund

|   |   | Formula               | For 2006  |
|---|---|-----------------------|-----------|
|   | Infants vaccinated/to be vaccinated with 1st dose of DPT-   |                       |           |
| A | Hep B(new vaccine)*   |                       | 1,501,695 |
|   |   |                       |           |
|   | Percentage of vaccines requested from The Vaccine Fund      |                       |           |
| В | taking into consideration the Financial Sustainability Plan | % "                   | 41%       |
| С | Number of doses per child                                   |                       | 3         |
| D | Number of doses   | $A \times B \times C$ | 1,847,085 |
| E | Estimated wastage factor                                    | (see list in table 3) | 1.05      |
| F | Number of doses (incl. Wastage)                             | A x C x E x B/100     | 1,939,439 |
| G | Vaccines buffer stock                                       | F x 0.25              | 484,860   |
|   | Anticipated vaccines in stock at start of year 2006         |                       |           |
|   | (including balance of buffer stock)                         |                       | 1182585   |
| 1 | Total vaccine doses requested                               | F + G - H             | 1,241,714 |
|   | Number of doses per vial                                    |                       | 10        |
| K | Number of AD syringes (+10% wastage)                        | (D+G-H) x 1.11        | 1,275,789 |
|   | Reconstitution syringes(+10% wastage)                       | I/J x 1.11            | 137,830   |
| M | Total safety boxes (+10% of extra need)                     | (K+L)/100 x 1.11      | 15,691    |

\*Please report the same figure as in table 3.

Table 5: Wastage rates and factors

|     | Die et trabenge rates and | A MILLEON D |      |      |      |      |      |      |      |      |      |      |      |
|-----|---------------------------|-------------|------|------|------|------|------|------|------|------|------|------|------|
| Va  | ccine wastage rate        | 5%          | 10%  | 15%  | 20%  | 25%  | 30%  | 35%  | 40%  | 45%  | 50%  | 55%  | 60%  |
| Equ | uivalent wastage factor   | 1.05        | 1.11 | 1.18 | 1.25 | 1.33 | 1.43 | 1.54 | 1.67 | 1.82 | 2.00 | 2.22 | 2.50 |

Remarks

| ı |     |  |                             |                         |                   |                        |                       |
|---|-----|--|-----------------------------|-------------------------|-------------------|------------------------|-----------------------|
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   | 3.3 | Confirmed/revised req                                | uest for injection safet    | y support for the year  | rs 2006 -2007     |                        |                       |
|   |     | Table 6: Estimated suppl<br>TT, and number them from | lies for safety of vaccinat | ion for the next two ye | ars with (Use one | table for each vaccine | BCG, DTP, measles and |
|   |     |  | ,                           |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             | ٠                       |                   |                        | ø                     |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             | **                      |                   | ×                      |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        |                       |
|   |     |  |                             |                         |                   |                        | 18                    |

|   |   | Formula                   | For 2006        | For 2007       |
|---|---|---------------------------|-----------------|----------------|
|   | Target if children for Vaccination (for TT: target of   |                           |                 |                |
| A | pregnant women) 1   | #                         |                 |                |
|   | Number of doses per child (for TT: target of pregnant   |                           |                 |                |
| В | women)  | #                         |                 |                |
| C | Number ofdoses  | AxB                       |                 |                |
| D | AD syringes (+10% wastage)  | C x 1.11                  |                 |                |
| E | AD syringes buffer stock 2  | D x 0.25                  |                 |                |
| F | Total AD syringes   | D+E                       |                 | -              |
| G | Number of doses per vial  | #                         |                 |                |
| Н | Vaccine wastage factor 4  | Either 2 or 1.6           |                 |                |
| I | Number of reconstitution syringes (+10% wastage) 3  | C x H X 1.11/G            |                 |                |
| J | Number of safety boxes (+10% of extra need)   | (F + I) x 1.11/100        |                 |                |
| I | Contribute to a maximum of 2 doses for Pregnant Women (estima   | nted as total births)     |                 |                |
| 2 | The buffer stock for vaccines and AD syringes is set at 25%. This introduce the vaccination in any given geographic area. Write zer |                           | ck of doses rec | juired to      |
| 3 | Only for lyophilized vaccines. Write zero for other vaccines.   |                           |                 |                |
| 4 | Standard wastage factor will be used for calculation of reconstitution YF   | on syringes. It will be 2 | for BCG, 1.6 f  | or measles and |

If quantity of current request differs from the GAVI letter of approval, please present the justification for that difference.

NA .

4. Please report on progress since submission of the last Progress Report based on the indicators selected by your country in the proposal for GAVI/VF support

\* See 1.3.2

| <ol><li>Signatures</li></ol>                          |   |   |                          |                     |                      |             |                |  |
|---|---|---|--------------------------|---------------------|----------------------|-------------|----------------|--|
| For the Government of                                 | UNITED REPL   | BLIC OF TA  | YUZANI F                 | +                   |                      |             |                |  |
|   | () (  | k.n.  | .y. KATIBU               | MKUU                |                      |             |                |  |
| Signature:  | - Miny  |   | WIZARA YA<br>S.L.P. 9083 |                     |                      |             |                |  |
| Title: DEPUT  | 1 MINISTER F  |   | TAR EC                   | SALAAM              |                      |             |                |  |
| Date: 21. 8   | 5. 2005   |   |                          |                     |                      |             |                |  |
| Financial accountability government audit requirement | nembers of the Inter-Age ) commitment on the part ty forms an integral part of irements as detailed in th government or partner rec | of the partner agence of GAVI/The Wacon e Banking formal Wh | ey or individ            | ual.                | country performance. | It is based | on the regular |  |
| Agency/Organisation                                   | Name/Title  | Date Signatur   |                          | Agency/Organisation | Name/Title           | Date        | C!4            |  |
| World Bauk  | E. G. Malangalila.  | Hay 5, in   | illustra.                | Agency/Organisation | Name/11tte           | Date        | Signature      |  |
|   | V   | MYZAMA  | 0                        |                     | o                    |             |                |  |
| MINISTRY OF HEALTH                                    | DE ALI A. MZIGE<br>DIRECTOR PRAV  | 11-55-20 AB   | Frank                    |                     |                      |             |                |  |
|   | FOR PERMANENT   | SECRETARY   |                          |                     |                      |             |                |  |
|   | . MINISTRY OF   | HEAT THE  |                          |                     |                      |             |                |  |
|   | P. O. Box 9<br>DAR ES SALA  | กลว   |                          |                     |                      |             |                |  |
|   | TO DALA   | (11)  |                          |                     |                      |             |                |  |

| 7. | Sig | na | tui | res |
|----|-----|----|-----|-----|
|    |     |    |     |     |

For the Government of UNITED REPUBLIC OF TANZANIA

Signature:

WIZARA YA AFYA

Title:

DEPUTY MINISTER FOR HEALTH DAN ES

21-5-2005

Date: 21 5 & 2005

We, the undersigned members of the Inter-Agency Co-ordinating Committee endorse this report. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Financial accountability forms an integral part of GAVI/The Vaccine Fund monitoring of reporting of country performance. It is based on the regular government audit requirements as detailed in the Banking form. The ICC Members confirm that the funds received have been audited and accounted for according to standard government or partner requirements.

| Agency/Organisation | Name/Title        | Date    | Signature       | Agency/Organisation | Name/Title | Date | Signature |
|---------------------|-------------------|---------|-----------------|---------------------|------------|------|-----------|
| Empaser reteach     | 13 Mc GRAFIH      | 10/01/0 | 5 Benful OM     |                     |            |      |           |
| Die de Colment      | CONFRACON TIRELAN |         | DNA ps          | °                   |            |      |           |
|                     |                   | S       | SSY OF IAE PART |                     |            |      |           |
|                     |                   | AMB     | o Z             |                     |            |      |           |
|                     |                   |         |                 |                     |            |      | d -       |
|                     |                   | 1       | AR EC CALARM    |                     |            |      |           |

| 7. Signatures  |                               |   |                          |                                 |
|--|-------------------------------|---|--------------------------|---------------------------------|
| For the Government of  |                               |   |                          |                                 |
| Signature:   |                               |   |                          |                                 |
| Title:   |                               |   |                          |                                 |
| Date:  |                               |   |                          |                                 |
| We, the undersigned members of the Inter-Agency Co-ordinating Committee<br>any financial (or legal) commitment on the part of the partner agency or indi-  |                               | ture of endorsement                         | of this docu             | ment does not imply             |
| Financial accountability forms an integral part of GAVI/The Vaccine Fund in government audit requirements as detailed in the Banking form. The ICC M according to standard government or partner requirements. | nonitoring of reporting of co | ountry performance.<br>nds received have be | It is based en audited a | on the regular nd accounted for |
| Agency/Organisation Name/Title Date  | Agency/Organisation           | Name/Title                                  | Date                     | Signature                       |
| WHO DREMAGNU WR. 06/05/65 Patertigon   |                               |   |                          |                                 |
| UNICE R. HILLIPS Rep. 9.5.05 MILLER  |                               |   |                          |                                 |
|  |                               |   |                          |                                 |
|  |                               |   |                          |                                 |

Date:

We, the undersigned members of the Inter-Agency Co-ordinating Committee endorse this report. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Financial accountability forms an integral part of GAVI/The Vaccine Fund monitoring of reporting of country performance. It is based on the regular government audit requirements as detailed in the Banking form. The ICC Members confirm that the funds received have been audited and accounted for according to standard government or partner requirements.

| Agency/Organisation | Name/Title                              | Date Signature                       | Agency/Organisation | Name/Title | Date | Signature |
|---------------------|---|--------------------------------------|---------------------|------------|------|-----------|
| MNH   Mucets        | DR Jesse A Kitumer<br>Head-Bener. Parel | 28/4/05 Jacquet                      |                     |            |      |           |
|                     | and child Health                        | Head, Department                     | Pediatrics          |            |      |           |
|                     |   | and Child Health.  Muhimbili Natione | Hospital,           |            |      |           |
|                     |   |                                      |                     |            |      |           |
|                     |   |                                      |                     |            |      |           |